ArticleEndocrine connections2025
A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the treatment of advanced neuroendocrine neoplasms in China.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surufatinib, an oral vascular immune kinase inhibitor targeting angiogenesis and immune escape, is approved in China for the treatment of unresectable locally advanced or metastatic neuroendocrine tumors (NETs). This real-world study aimed to evaluate its efficacy and safety in neuroendocrine neoplasms (NENs), including neuroendocrine carcinomas (NECs). From 2022 to 2024, 21 patients (12 with NET and 9 with NEC) at Nanjing Drum Tower Hospital received surufatinib-based therapy. The median follow-up period was 690 days. The primary endpoint, the disease control rate, was 81% (95% confidence interval (CI): 58.1-94.6), and the objective response rate (ORR) was 14% (95% CI: 3.0-36.3). The ORR was 8.3% (95% CI: 0.2-38.5) in NET and 44.4% (95% CI: 13.7-78.8) in NEC, with no significant difference by Fisher's exact test (P = 0.119). The median progression-free survival (mPFS) was 9.7 months (95% CI: 2.5-15.9), while the median overall survival (mOS) had not been reached. For first-line treatment, the mPFS was 9.7 months (95% CI: 3.5-15.9) in NET patients and 15.1 months (95% CI: 3.8-26.5) in NEC patients; for second-line treatment, it was 6.7 months (95% CI: 0.9-12.4) in NET patients and 4.6 months (95% CI: 1.7-7.6) in NEC patients. Treatment-related adverse events (TRAEs) of grade ≥3 occurred in 28% of patients, and no treatment-related deaths were reported. Patients with TRAEs ≥1 (hazard ratio 0.349, P = 0.048) had longer PFS. This study supported the activity of surufatinib in advanced NENs; subgroup findings, including those for NEC, were exploratory and required confirmation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.